Laroche M, et al. - The researchers aimed to assess the variability of densitometric response to Denosumab (Dmab), given in the second line, in postmenopausal osteoporosis. They also tried to understand the reasons. They found a highly variable Dmab densitometric response, which was partly explained by the duration of previous treatments and the level of bone resorption at initiation of treatment.